News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Solvay Pharmaceuticals, Inc. Release: CREON(R) (Pancrelipase) Delayed-Release Capsules Significantly Improves Fat Absorption in Children with Cystic Fibrosis, Study in Clinical Therapeutics Reports


2/5/2010 10:09:30 AM

Bookmark and Share

MARIETTA, Ga., Feb. 5 /PRNewswire-FirstCall/ -- Solvay Pharmaceuticals, Inc. announced today that Phase IIIb data published in the January issue of Clinical Therapeutics confirm that CREON® (pancrelipase) Delayed-Release Capsules significantly improves a key measure of fat absorption in children aged 7-11 years who have exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF), EPI is a condition resulting from a deficiency in the production and/or secretion of pancreatic enzymes that are necessary to digest nutrients in food.

Read at News Release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES